Two Sigma Investments
KYTX icon

Two Sigma Investments’s Kyverna Therapeutics KYTX Stock Holding History

Two Sigma Investments’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Sell
181,615
-23,652
-12% -$197K ﹤0.01% 2946
2025
Q4 		$1.93M Buy
205,267
+72,816
+55% +$541K ﹤0.01% 2465
2025
Q3 		$795K Buy
132,451
+11,867
+10% +$47.4K ﹤0.01% 2730
2025
Q2 		$370K Sell
120,584
-2,393
-2% -$5.92K ﹤0.01% 2709
2025
Q1 		$237K Sell
122,977
-58,677
-32% -$173K ﹤0.01% 2802
2024
Q4 		$679K Buy
181,654
+58,800
+48% +$282K ﹤0.01% 2385
2024
Q3 		$601K Sell
122,854
-33,442
-21% -$258K ﹤0.01% 2378
2024
Q2 		$1.17M Buy
156,296
+135,454
+650% +$2.07M ﹤0.01% 1902
2024
Q1 		$518K Buy
+20,842
New +$582K ﹤0.01% 2314

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Two Sigma Investments's KYTX Position: Q1 2026 in Review

Two Sigma Investments reduced its Kyverna Therapeutics (KYTX) stake by 12% in Q1 2026, selling an estimated $197K and leaving 181,615 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

Two Sigma Investments first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.93M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Two Sigma Investments held 181,615 shares of Kyverna Therapeutics worth $1.57M as of Q1 2026.
  • Two Sigma Investments sold 23,652 Kyverna Therapeutics shares in Q1 2026, an estimated $197K.
  • Kyverna Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2946 holding.
  • Two Sigma Investments first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Two Sigma Investments's Kyverna Therapeutics position peaked at $1.93M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.